Hong Kong PR

Key Highlights:Hiring activity in Singapore saw recovery with a 3% month-on-month growth while witnessing an annual dip of 5% in February’25Advertising, Public Relations & Media sector and the Education sector lead with 7% month-on-month growth in February '25Hiring for Software, Hardware, and Telecom roles record the highest growth at 2% month-on-month Legal sector saw the strongest annual growth at 19% year-on-yearSINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - foundit (formerly Monster APAC & ME), one of the leading jobs and talent platform, today published the foundit Insights Tracker (fit) Singapore for February 2025. The Singapore fit report highlights growth in the Advertising and Education sectors alongside rising demand for technology professionals.The tracker reveals an overall year-on-year (YoY) decline of 5% in hiring activity across sectors, as the index dropped from 108 in February 2024 to 103 in February 2025. However, a month-on-month (MoM) analysis indicates a 3% uptick,Commenting on Singapore's job trends for February 2025, V Suresh, CEO, foundit, said,“The February 2025 foundit Insights Tracker signals a promising recovery in Singapore’s job market. While year-on-year figures reflect ongoing economic recalibration, the month-on-month growth indicates a resurgence in hiring activity. The robust expansion of sectors such as Advertising, Media, and Education, coupled with the growing demand for technology professionals, underscores shifting industry priorities and workforce evolution. As digital transformation accelerates, Singapore’s job landscape is stabilizing, with a strong emphasis on upskilling, adaptability, and future-ready talent."Advertising, and Education sectors lead industry growth, while Engineering and Retail sectors show strong improvementsThe Advertising, Market Research, Public Relations, Media, and Entertainment sector has emerged as a frontrunner in e-recruitment activity among all monitored industries, showing a 7% MoM growth in February 2025. This growth is driven by increased digital marketing efforts and brand-building strategies.Equally impressive, the Education sector also recorded 7% MoM growth in February 2025, reflecting a continued emphasis on workforce upskilling and professional development.Following these leaders, the Engineering, Construction, and Real Estate sector showed positive trends with 6% MoM growth, while the Retail, Trade, and Logistics sector experienced 5% MoM growth, both driven by sustainability initiatives and evolving business needs.Several sectors show modest growth while others remain stableThe Production/Manufacturing, Automotive, and Ancillary sector demonstrated positive hiring momentum with 5% MoM growth in February 2025.Several sectors showed more modest growth, with Hospitality & Travel, IT, Telecom/ISP, and BPO/ITES, BFSI, and Healthcare all registering 2% MoM increases, signalling steady job creation across these industries.Conversely, multiple sectors including Oil and Gas, Import/Export, Shipping/Marine, Government/PSU/Defence, and Consumer Goods/FMCG exhibited stagnant hiring activity with 0% MoM change.Technology roles lead demand among functionsIn terms of functions, Software, Hardware, and Telecom witnessed the highest demand in February 2025, with a 2% MoM increase. This trend underscores the growing need for tech talent amid ongoing digital transformation initiatives.Marketing & Communications, HR & Admin, Engineering/Production, Sales & Business Development, Medical Roles, and Legal roles all showed modest but positive growth at 1% MoM, indicating broad but measured hiring activity across professional functions.The roles in Legal experienced a robust   19% YoY increase in hiring activity, highlighting the rising need for legal professionals amid evolving regulatory landscapes, corporate expansions, and compliance requirements.However, Hospitality Roles, Customer Service, Finance & Accounts, and Purchase/Logistics/Supply Chain roles saw no changes (0% MoM), reflecting a period of stability in workforce demand across these functions.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring. Additionally, foundit has been recognised as a Great Place to Work, reflecting its dedication to fostering a supportive and dynamic work culture.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata Sharma – Namrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

- ComfortDelGro, a leading multi-modal mobility transport operator, introduces a new purpose statement to reflect its commitment to driving positive impact for a better future. - Refreshed logo and corporate identity underscores the company’s journey as a global, progressive, and collaborative mobility leader. SINGAPORE, Mar 24, 2025 - (ACN Newswire via SeaPRwire.com) - ComfortDelGro Corporation Limited (SGX:C52) (“ComfortDelGro” or, “The Group”) today, unveiled its refreshed corporate brand, comprising a new purpose statement and modern visual identity that signifies a step forward in the company’s evolution into a global multi-modal transport leader. The Group has made significant strides in growing its international business, winning bus and rail tenders in Europe and Australia, as well as building leading positions for its point-to-point mobility businesses in key markets. With a presence in 13 countries, 24,500 employees, an operating fleet of over 54,000 vehicles and a rail network of 343 kilometres in operation and under mobilisation, ComfortDelGro is one of the largest land transport companies in the world. ComfortDelGro Managing Director/Group CEO Cheng Siak Kian said, “Our purpose statement – Mobility for a better future, drives us to reimagine mobility as a catalyst for positive impact as we accelerate our growth and navigate new horizons. It reflects our commitment to addressing the changing needs of our stakeholders as a global multi-modal transport leader. At the same time, it aligns the Group’s diverse operations and workforce under the common goal of building a purpose-driven and values-led organisation.” ComfortDelGro Chairman Mark Greaves added, “The transport landscape is evolving, and so is ComfortDelGro. We are committed to sustainable mobility, powered by innovation and driven by collaboration. This brand refresh underpins our journey forward as a global, progressive, and collaborative mobility company while building on the strong foundation of our businesses and our rich heritage. Our purpose ‘Mobility for a better future’ will guide us as we continue to create long-term value for our stakeholders, shape the future of transportation, and contribute to a more sustainable and connected world." Driven by our new purpose: Mobility for a better futureA modern identityComplementing our purpose statement is an updated ComfortDelGro logo that symbolises the company’s journey forward and its commitment to delivering innovative, world-class mobility solutions. Key elements include:A refined blue hue, representing reliability, trust, and customer confidence.A streamlined lowercase font, conveying approachability and collaboration.An enhanced arrow motif, reinforcing the company’s forward-thinking and dynamic approach.The updated brand and corporate identity will be gradually implemented in stages across the Group’s global operations.Media Assets:High-resolution images can be downloaded here: https://fromsmash.com/cdgbrandrefreshAbout ComfortDelGro CorporationComfortDelGro is a leading multi-modal transport operator offering a comprehensive suite of transportation solutions. Our extensive network spans public transport including buses and rail, point-to-point transport with taxis and private hire cars as well as business-to-business mobility solutions. Every day, millions rely on our services across 13 countries including; Singapore, Australia, the United Kingdom, New Zealand, China, Ireland, Sweden, France, Malaysia, Spain, Portugal, Greece, and the Netherlands. As a global operator, we play an important role in steering the transition towards a low-carbon economy. With about 60% of our owned fleet consisting of cleaner energy vehicles, we support governments and cities in enabling inclusive and sustainable transport systems. For our efforts, ComfortDelGro has been included in the Dow Jones Best-in-Class Indices since 2019, the only Singaporean transport company in the index. Media Contact Information:Group Corporate Communications  ComfortDelGro Corporation Limited groupcorpcomms@comfortdelgro.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights For the Year Ended 31 December RMB20242023Change RMB’BillionRMB’Billion(%)Revenue28.8726.20+10.2%Gross profit margin (%)81.5%81.0%+0.5pptSelling and administrative expenses to revenue ratio (%) *42.1%42.2%-0.1pptR&D expenses to revenue ratio (%)17.6%16.8%+0.8pptProfit for the year6.365.10+24.9%Profit attributable to owners of the parent **3.502.33+50.1%Adjusted non-HKFRS profit attributable tothe owners of the parent *** 3.46 2.59 +33.5%Basic earnings per share, based on adjusted non-HKFRS profit attributable to the owner of the parent (RMB cents) 18.90 13.97 +35.3%Sales of innovative products ****12.069.89+21.9%Share of revenue (%)41.8%37.8% Sales of new products*****10.098.05+25.4%Share of revenue (%)35.0%30.7% Dividend per share (HK cents)7.05.0+40.0%- Interim3.02.0+50.0%- Final4.03.0+33.3%*The total of selling and distribution costs and administrative expenses divided by revenue**The significant year-on-year increase in profit attributable to the owners of the parent was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year***It refers to the basic earnings attributable to the owners of the parent after excluding impacts of discontinued operations, certain non-cash items and the share of profits and losses of associates and joint ventures.****Sales is the gross sales amount minus the sales discount. Innovative products include innovative drugs and biosimilars*****Products launched within five yearsDevelopment HighlightsOncology Innovative Drugs- Focus V (Anlotinib Hydrochloride Capsules) has been approved for seven indications. The marketing applications of three new indications have been submitted to the Center for Drug Evaluation of the China National Medical Products Administration (“CDE”), while another three pivotal clinical trials for new indications have shown positive results. The Group will submit new marketing applications to the CDE for these indications in the near future. In addition, anlotinib is in Phase III clinical studies for a number of new indications, including first-line non-squamous non-small cell lung cancer and first-line colorectal cancer. It is expected that marketing applications will be submitted gradually in the next few years.- Yilishu (Efbemalenograstim alfa Injection) has completed three global multi-center, randomized, and controlled pivotal Phase III clinical trials, and has been compared with the commonly used short-acting and long-acting G-CSF drugs in clinical practice, proving its efficacy and safety. In December 2023, Efbemalenograstim alfa was successfully included in the NRDL, and its sales volume accelerated in 2024, becoming an important contributor to the Group’s revenue growth.- Anfangning (Garsorasib Tablets) is a novel and highly effective KRAS G12C inhibitor that was approved for marketing by the NMPA in November 2024 for the treatment of advanced non-small cell lung cancer with KRAS G12C mutation that has received at least one systemic treatment. The Group will further explore the multi-indication potential of garsorasib, which is expected to become another blockbuster product in the oncology field.- Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection), and Paletan (Pertuzumab Injection) were approved for marketing by the NMPA in February 2023, May 2023, July 2023, and December 2024, respectively. The rapid increase in the volume of these biosimilars in 2024 has accelerated the Group’s revenue growth.Liver Disease Innovative Drugs- Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. Magnesium isoglycyrrhizinate is the world’s first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety.- Lanifibranor (pan-PPAR agonist) is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.Respiratory Innovative Drugs- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national Volume-based Procurement (“VBP”). The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP, enabling its sales to achieve steady growth in 2024.- Tianyun (Colistimethate Sodium for Injection) is a first-to-market generic drug launched in 2021. It is China’s first colistimethate sodium for injection approved for marketing, and was successfully included in the NRDL in 2023. At present, only two products with the same generic name have been approved in China. The Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly in 2024.Surgery/Analgesia Innovative Drugs- Zepolas (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth in 2024. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing in 2025.Others- In 2024, the tenth batch of VBP products accounted for only 1% of the Group’s total revenue, and the related risks have basically been removed. In addition, Anboni (Unecritinib Fumarate Capsules) and Anluoqing (Envonalkib Citrate Capsules), two category 1 innovative drugs independently developed by the Group, were newly included in the NRDL and are expected to benefit more patients.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2024.During the year, the Group recorded revenue of approximately RMB28.87 billion, an increase of approximately 10.2% over last year. Profit attributable to the owners of the parent company was approximately RMB3.50 billion, a substantial increase of approximately 50.1% over last year. Earnings per share attributable to the owners of the parent company were approximately RMB19.13 cents, a significant increase of approximately 51.9% over last year, which was mainly driven by the notable growth in revenue and the gain on disposal of subsidiaries during the year. Excluding the profit attributable to the owners of the parent from the discontinued operations, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), one-off adjustments for the impairment and fair value changes of certain assets and liabilities (net of related tax and non-controlling interests), fair value losses/(gains) of current equity investments (net of related tax and non-controlling interests), share-based payments (net of related tax and non-controlling interests), effective interest expenses and exchange (gain)/loss of the convertible bond debt component, adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB3.46 billion, an increase of approximately 33.5% over last year. The Group's liquidity remains strong, with total fund reserve at approximately RMB24.11 billion, including cash and bank balances classified under current assets of approximately RMB9.57 billion, bank deposit classified under non-current assets of approximately RMB9.37 billion, and the wealth management products of approximately RMB5.17 billion in aggregate.The Board of Directors has recommended a final dividend payment of HK4 cents per share (2023: HK3 cents). Together with the interim dividend of HK3 cents already paid, the total dividend for the year amounted to HK7 cents (2023: HK5 cents).Sales: Robust sales system continues to drive results  Achieves positive revenue growth for  generic drugsOn the strong foundation its generic drug business provides, the Group has comprehensively promoted innovation and transformation. The innovative products have kept boosting sales growth, with share of revenue climbing year after year. Revenue from innovative products amounted to RMB12.06 billion, up by 21.9% year-on-year, and accounted for 41.8% of the Group's total revenue.During the year, the sales of oncology medicines amounted to approximately RMB10.73 billion, representing approximately 37.2% of the Group’s revenue. The sales of surgery/analgesia and liver disease amounted to approximately RMB4.46 billion and RMB3.44 billion, respectively, representing approximately 15.4% and 11.9% of the Group's revenue, respectively. In addition, sales contributions from various areas such as respiratory, cardio-cerebral vascular medicines and others have continued to contribute to the Group's revenue. Among them, the sales of respiratory and cardio-cerebral vascular medicines accounted for approximately 10.9% and 7.5% of the Group's revenue, respectively.R&D: Pushes at full force innovative product development  Actively applies for various patentsThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver diseases, respiratory and surgery/analgesia. As at the end of the reporting period, the Group had 70 innovative products under development, including 39 oncology products, 7 liver disease products, 13 respiratory products, and 6 surgery/analgesia products, and 5 other products. In addition, the Group had 65 generic drug products in development.The Group also attaches tremendous importance to the protection of intellectual property rights and encourages its member enterprises to file patent applications in order to enhance the Group’s core competitiveness. During the reporting period, the Group filed 1,069 new patent applications and received 349 patent invention approvals. As at the end of the reporting period, the Group had accumulated 5,082 effective patents and patent applications and obtained 1,958 patent invention approvals.Prospects: Focuses on core business and innovation  Continues to promote dual-pronged approach in implementing globalization strategyThe Chinese pharmaceutical market has occupied a key position in the global pharmaceutical industry due to its huge volume and increasing market demand. In addition, as a strategic industry closely linked to the national economy and people’s livelihood, the pharmaceutical industry receives key support from national policies and incentives. Meanwhile, a series of policies is expected to broaden the pricing flexibility of innovative drugs, improve their accessibility, and create a wider market prospect for such drugs.Committed to its vision “to be a leading global pharmaceutical company through delivering innovative therapies for patients”, the Group has adhered to comprehensive innovation, stepped up its R&D investment, and continued to strengthen its internal R&D capabilities. It has now built a comprehensive pipeline and product portfolio. At the same time, the Group has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises.At present, the Group has entered the harvest period of its innovative development. It is expected that by 2027, the number of innovative products launched to the market will exceed 30, with revenue from innovative products accounting for over 55% of total revenue. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for the future sustainable growth. In addition, the Group has advanced its digitalization strategy with artificial intelligence (AI) as the core driving force. It has finished locally deploying cutting-edge AI models including DeepSeek and ChatGPT, and optimized key business such as cross-departmental collaboration, thereby significantly improving operational efficiency.Meanwhile, the Group adopts its dual-pronged globalization strategy to accelerate innovation and development. The Group will bring global pharmaceutical innovations to China to benefit Chinese patients, while also expanding its presence in international markets to target unmet clinical needs worldwide.Looking ahead, the Group will further focus on its core business and innovation, and continue to improve R&D efficiency and quality in the four major therapeutic areas. It will also actively accelerate the deployment for globalization of its business to drive rapid business growth and steady performance improvement, and contribute to the development of the global pharmaceutical industry.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for six consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI), a world leader in unmanned aircraft systems (UAS), has received the prestigious EMAR/FR 145 Maintenance Organization Approval for component maintenance from the French Military Continuing Airworthiness Authority, DSAE. This approval underscores GA-ASI's commitment to the highest standards of safety, compliance, and operational excellence in military aviation.The EMAR framework is a set of regulations developed from commercial aerospace standards (FAA/EASA) that are designed to ensure airworthiness for European military aircraft. It establishes a common airworthiness framework recognized by military airworthiness authorities worldwide. EMAR/FR 145 certification authorizes maintenance organizations to perform critical maintenance tasks while ensuring strict adherence to safety, reliability, and documentation requirements.GA-ASI's EMAR/FR 145 approval allows the company to issue EMAR Form 1s (Return to Service forms) for components serviced by the approved maintenance organization, confirming the safety and airworthiness of the equipment. This recognition applies to GA-ASI's maintenance activities at its Poway and Adelanto, California, facilities and covers CAT C (component maintenance) services."This approval is a significant achievement for GA-ASI, positioning the company to better serve international customers, especially military users of our MQ-9A and MQ-9B UAS platforms," said Sam Richardson, GA-ASI vice president of Sustainment. "The ability to leverage the EMAR/FR 145 certification streamlines the company's processes, reduces costs, and accelerates future airworthiness pursuits, as many future customers will recognize this certification rather than requiring a full, independent certification process."By obtaining EMAR/FR 145 approval, GA-ASI further demonstrates its ability to meet the stringent demands of the global defense market. The framework's widespread recognition ensures that GA-ASI can expand operations and offer high-quality, compliant maintenance services to international customers, ultimately driving company growth in global markets.This certification offers significant operational and financial benefits for both GA-ASI and its customers. For GA-ASI, the approval reduces future oversight costs by leveraging the DSAE Audit Team's oversight activities, ensuring a more efficient and cost-effective certification process for future non-French EMAR customers. For customers, the EMAR/FR 145 approval provides a framework recognized internationally, offering a streamlined maintenance certification process. The recognition agreements between EMAR and non-EMAR countries allow future customers to leverage GA-ASI's French approval, saving time and resources compared to a full certification effort.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

Highlights of the Global Offering:- The Hong Kong Public Offering is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025;- Offer Price Range: HK$2.50 to HK$3.00 per Share;- The Shares will be traded in board lots of 1,000 Shares each;- Maximum net proceeds will be approximately HK$117.7 million (before any exercise of the Over-allotment Option);- Dealings in the Shares on the Main Board of the Hong Kong Stock Exchange are expected to commence on Monday, 31 March 2025;- Red Solar Capital Limited is the Sole Sponsor.HONG KONG, Mar 21, 2025 - (ACN Newswire via SeaPRwire.com) - Jiangsu Horizon Chain Supermarket Company Limited (the “Company”, stock code: 2625) today announces its Global Offering and the listing of Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Jiangsu Horizon Chain Supermarket Company Limited is a wholesaler of grains and oil headquartered in Yangzhou, with retail operations of supermarket and convenience stores focusing on the central region of Jiangsu Province under the brand 'Hongxinlong'. According to the Industry Report, the Company ranked second among supermarket operators in Yangzhou in terms of sales in 2023 with a market share of approximately 9.1%, the fifth among supermarket operators in the central region of Jiangsu Province in terms of sales in 2023 with a market share of approximately 2.3%, and around the twentieth among supermarket operators in Jiangsu province in terms of sales in 2023 with a market share of approximately 0.4%.Jiangsu Horizon Chain Supermarket Company Limited plans to offer an aggregate of 53,562,000 Shares (subject to Over-allotment Option) under the Global Offering, of which 48,205,000 Shares (subject to reallocation and the Over-allotment Option) will be offered by way of International Placing, and 5,357,000 Shares (subject to reallocation) will be offered in the Hong Kong Public Offering. The Offer Price will not be more than HK$3.00 per Share and is currently expected to be not less than HK$2.50 per Share, with the board lot size of 1,000 sharesThe Hong Kong Public Offering commenced on Friday, 21 March 2025 and is expected to close at 12:00 noon (at 11:30 a.m. for completing electronic applications under the White Form eIPO service) on Wednesday, 26 March 2025. Dealings in H Shares on the Stock Exchange are expected to commence on Monday, 31 March 2025.Assuming the Over-allotment Option is not exercised at all, if the Offer Price is set at HK$3.00 per Share (being the high end of the Offer Price range), the net proceeds from theGlobal Offering will increase to approximately HK$117.7 million. The Company intends to apply the net proceeds for the following purposes:- Approximately 30.9% will be used for the opening of new Retail Stores, including store renovation, purchase of shelves, purchase of cold storage facilities, lightings, air-conditioning, CCTV surveillance system and POS system and installation of fire safety system.- Approximately 41.2% will be used for establishing a new distribution centre including acquiring a parcel of land for the construction of the New Distribution Centre, acquiring shelves, lightings and ancillary facilities and installing fire safety system.- Approximately 26.8% will be used for establishing a new central kitchen, including the construction of the New Central Kitchen, acquiring machines and equipment, acquiring and installing fire safety system, ventilation system, cold storage facilities, utilities, air-conditioning, CCTV surveillance system and ancillary facilities, and acquiring additional vehicles for the delivery of meals to the customers.- Approximately 1.1% will be used for enhancing the ERP system and infrastructure systems to improve operational efficiency.The Company has successfully procured cornerstone investor Top Legend SPC, Top Legend has agreed to subscribe for such number of H Shares which may be subscribed with an aggregate amount of US$5.0 million at the Offer Price (including brokerage, SFC transaction levy and Stock Exchange trading fee). The lock-up period shall last for a duration of six months.Red Solar Capital Limited is the Sole Sponsor. Red Solar Capital Limited and CMBC Securities Company Limited are the Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CCB International Capital Limited is the Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. CMB International Capital Limited, uSMART Securities Limited, Star River Securities Limited, Eddid Securities and Futures Limited, Innovax Securities Limited, and Long Bridge HK Limited are the other Joint Bookrunners and Joint Lead Managers. Copyright 2025 ACN Newswire via SeaPRwire.com.